Leukemia

Dr Stein elaborates on some practical considerations for the use of venetoclax and hypomethylating agents for the treatment of patients with chemotherapy-ineligible acute myeloid leukemia.

An expert lists the information physicians consider when choosing a first-line therapy for patients with chemotherapy-ineligible acute myeloid leukemia.

Eytan Stein, MD, discusses the predictive and prognostic factors for patients with chemotherapy-ineligible acute myeloid leukemia.

An expert explains the first-line treatment options for patients with chemotherapy-ineligible acute myeloid leukemia.

Dr Stein elaborates on the impact of the approval of small molecule inhibitors for the treatment of acute myeloid leukemia.

Eytan Stein, MD, discusses the therapeutic standards of care for newly diagnosed adult patients with acute myeloid leukemia.

Combination ivosidenib/azacitidine has yielded notable improvements in survival over ivosidenib alone in IDH1-positive treatment-naïve acute myeloid leukemia.

Older adult patients with newly diagnosed high-risk or secondary acute myeloid leukemia experienced a durable survival benefit when treated with CPX-351 over 7+3 cytarabine and daunorubicin chemotherapy.

The SEQUOIA trial comparing zanubrutinib with bendamustine plus rituximab for patients with treatment-naïve chronic lymphocytic leukemia demonstrated superior progression-free survival results with the BTK inhibitor.

Patients with Philadelphia chromosome–negative acute lymphocytic leukemia who have hypersensitivity to pegylated asparaginase may benefit from eryaspase treatment.

A phase 1/2 trial featuring lanraplenib/gilteritinib in patients with FLT3-mutant acute myeloid leukemia will proceed following the FDA’s clearance of an investigational new drug application.

CancerNetwork® sat down with Julie Vose, MD, MBA, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about a clinical trial comparing acalabrutinib versus ibrutinib for patients with chronic lymphocytic leukemia.

CancerNetwork® spoke with Jeffery Auletta, MD, about how the National Marrow Donor Program/Be The Match is using research initiatives to expand eligibility for stem cell transplants in for patient with acute leukemias and myelodysplastic syndrome.

Results of a phase 2 trial show that ibrutinib was capable of inducing responses in some patients with hairy cell leukemia who were previously treated with standard therapy options in a prior line.

The phase 2 GIMEMA LAL1913 trial identified poor outcomes and increased minimal residual disease persistence among patients with Philadelphia-like acute lymphoblastic leukemia.

A new study has adapted CAR to look more human to the body, which will then in turn yield longer remission rates for pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

The updated results of an ongoing phase 1/2 study indicated that CA-4948 achieved promising responses and a tolerable safety profile in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.

In a trial of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and other hematologic cancers, the BCL-2 inhibitor lisaftoclax demonstrated feasibility as a treated option in the relapsed or refractory setting.

Ibrutinib and venetoclax may prove beneficial in previously untreated chronic lymphocytic leukemia.

Update from a preplanned clinical trial analysis shows promise of devimistat in relapsed/refractory acute myeloid leukemia.

Approval of asparaginase erwinia chrysanthemi (recombinant)-rywn represents a long-awaited alternative to E. Coli–derived asparaginase for patients with acute lymphoblastic leukemia.

SNDX-5613 has received a fast track designation from the FDA for the treatment of relapsed/refractory acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia.

CYNK-001, a human placental hematopoietic stem cell–derived natural killer cell infusion, will now be tested in an expanded population following promising results in a phase 1 trial.

Paolo Ghia, MD, PhD, discussed data from the CAPTIVATE trial of ibrutinib/venetoclax in the frontline setting for chronic lymphocytic leukemia.

All patients with chronic lymphocytic leukemia who were treated with zanubrutinib in the relapsed/refractory setting showed impressive responses.

A trial of an eprenetapopt combination has met the prespecified primary efficacy end point in patients with acute myeloid leukemia harboring TP53 mutations.

Results of the phase 1 portion of ZUMA-4 support continued investigation into the efficacy of KTE-X19 in pediatric patients with B-cell acute lymphoblastic leukemia.

Avapritinib is now fully approved to treated advanced systemic mastocytosis, according to phase 1 and phase 2 clinical trial data.

A progression-free survival advantage persisted at the 3-year mark with venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia.

The risk of progression or death was statistically significantly reduced with the use of ibrutinib and venetoclax versus chlorambucil plus obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.